Kymriah

Tisagenlecleucel, the active ingredient in Kymriah, is a CAR T‑cell therapy presented as an autologous cell infusion for intravenous use. It treats relapsed or refractory B‑cell acute lymphoblastic leukemia in patients up to 25 years of age and relapsed or refractory diffuse large B‑cell lymphoma in adult patients.

GNH USA supplies Kymriah as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Kymriah is a CAR T‑cell immunotherapy that targets CD19‑positive B‑cell malignancies. - Relapsed or refractory B‑cell acute lymphoblastic leukemia (ALL): provides targeted cellular therapy that can induce remission in patients up to 25 years of age. - Relapsed or refractory diffuse large B‑cell lymphoma (DLBCL): offers an option for adult patients whose disease has not responded to standard treatments. - CD19‑positive B‑cell malignancies (general): enables selective cytotoxicity against malignant B cells expressing the CD19 antigen.

Kymriah can be associated with a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Cytokine release syndrome: fever, hypotension, and flu‑like symptoms occurring shortly after infusion. - Fatigue: persistent tiredness reported during the first weeks post‑treatment. - Nausea: mild to moderate gastrointestinal upset. - Headache: transient cranial discomfort.

Serious or Rare Side Effects: - Neurotoxicity: encephalopathy, seizures, or aphasia that may require intensive monitoring. - Severe infections: opportunistic bacterial, viral, or fungal infections due to immune suppression. - Prolonged cytopenias: lasting low blood counts that increase bleeding or infection risk. - Tumor lysis syndrome: rapid tumor breakdown leading to metabolic disturbances.

Clinicians should observe several precautions when administering Kymriah to minimize risks. - Patient monitoring: observe for cytokine release syndrome and neurotoxicity during the first 30 days post‑infusion. - Infection control: screen for active infections and avoid live vaccines before and after therapy. - Cardiac assessment: evaluate baseline cardiac function as hypotension and arrhythmias may occur. - Hematologic surveillance: regularly check blood counts to detect prolonged cytopenias. - Store at 2-8°C: keep the cell product refrigerated, protect from light, do not freeze or shake.

Kymriah may interact with other agents that affect immune function or cytokine activity.

Major Interactions (Avoid): - Live attenuated vaccines: administration can cause uncontrolled infection due to immunosuppression. - Concurrent strong immunosuppressants: may exacerbate infection risk and diminish therapeutic efficacy. - High‑dose corticosteroids during infusion: can blunt CAR T‑cell expansion and reduce response.

Moderate Interactions (Monitor Closely): - Antimicrobial prophylaxis agents: adjust dosing to avoid overlapping toxicities. - Cytokine‑targeting therapies (e.g., tocilizumab): may be required to manage cytokine release syndrome but should be coordinated with the treatment team. - Other cellular therapies: schedule spacing to prevent overlapping immune activation.